NEXR-TECHNOLOGIES-SE
30.9.2021 18:49:09 CEST | Business Wire | Press release
NeXR Technologies SE (XETRA: NXR ) has reached one more milestone in its groundbreaking cooperation with H&Mbeyond. By installing the Fusion III body scanner developed by NeXR Technologies and starting the test phase of the AvatarCloud Fashion application, H&M Germany is opening selected stores for virtual fitting of its new collection. From 14 October to 6 November this year, H&M customers will have the opportunity to virtually try on perfect-fit looks from the new collection from home and outside of store opening hours via "digital fitting rooms" in two stores in Berlin and one H&M store in Hamburg.
As part of the test phase, customers can have a personal avatar, a digital twin, created free of charge with their exact body measurements in the scanners of participating H&M stores. The innovative AvatarCloud app from NeXR Technologies allows customers to try on the matching styles of around 30 pieces of apparel from the new collection on their own avatar. An expansion of the virtual fitting offer to further collections is already technically possible.
NeXR Technologies SE: H&M Germany opens selected stores for virtual fitting with AvatarCloud app
The technology, developed by NeXR and driven forward in collaboration with H&Mbeyond. for use in fashion retail, strives not only to offer an exciting digital shopping experience but also to analyze together with customers what impact "digital fitting rooms" can have on shopping behavior. H&Mbeyond. the Berlin-based innovation lab of H&M Germany, is responsible for developing and piloting innovative products and services relevant to H&M's global organization.
Markus Peuler, Managing Director of NeXR Technologies SE: "We are very proud that H&Mbeyond. awarded us as a trusted partner in their innovation work immediately with the test operation in three of their major stores. With our Virtual Fitting solution for H&M Germany, we have reached another milestone in the roll-out of our products announced for the current financial year. We are confident that this cooperation will also enable us to make a long-term contribution to sustainability in the textile industry. That is a very important matter for us."
The AvatarCloud app is available on the Apple AppStore and Google Play . For more information on AvatarCloud and the new H&M collection, please visit: avatar.cloud .
About NeXR Technologies
NeXR Technologies SE from Berlin (XETRA: NXR ) is a listed technology company with a focus on virtual reality applications. The core of the company consists of personalized, digital avatars that support users in performing everyday tasks more efficiently. These include the visualization of training successes on one's own avatar (NeXR Fitness), the virtual fitting of clothing (NeXR Fashion) or the participation in and the design of virtual live events (NeXR Show) and remote presentations (NeXR Seminar). NeXR Technologies has core competencies in 3D scanner development, motion capture, virtual reality, virtual production as well as deep understanding in gaming and data-based business models. Based on two self-developed multi-user and multi-purpose platforms, NeXR Technologies offers products and solutions for numerous user industries. NeXR Technologies SE is listed in the General Standard of the Frankfurt Stock Exchange. For more information, please visit www.nexr-technologies.com .
About H&M
H & M Hennes & Mauritz AB (publ) was founded in Sweden in 1947 and is quoted on Nasdaq Stockholm. H&M's business idea is to offer fashion and quality at the best price in a sustainable way. In addition to H&M, the group includes the brands COS, Monki, Weekday, & Other Stories, H&M HOME and ARKET as well as Afound. The H&M group has 51 online markets and more than 5,000 stores in 74 markets including franchise markets. In 2019, net sales were SEK 233 billion. The number of employees amounts to more than 179,000. For further information, visit hmgroup.com .
Language: |
English |
Company: |
NEXR Technologies SE |
Charlottenstraße 4 |
|
10969 Berlin |
|
Germany |
|
Phone: |
+49 (0) 30 403 680 143 |
Fax: |
+49 (0) 30 403 680 141 |
E-mail: |
|
Internet: |
|
ISIN: |
DE000A1K03W5 |
WKN: |
A1K03W |
Listed: |
Regulated Market in Berlin, Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005829/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom